Company Filing History:
Years Active: 2022-2025
Title: Innovations by Conn Hastings in Cancer Treatment
Introduction
Conn Hastings is an accomplished inventor based in Dublin, Ireland. He has made significant contributions to the field of medical technology, particularly in cancer treatment. With a focus on developing innovative solutions, Hastings has been awarded 2 patents for his groundbreaking work.
Latest Patents
Hastings' latest patents include a thermo-responsive hydrogel designed for intratumoral administration as a treatment for solid tumor cancers. This innovative hydrogel is a room temperature injectable formulation that comprises a P407 poloxamer base hydrogel, chitosan, 2-Hydroxypropyl β-cyclodextrin, and genipin. The unique combination of chitosan and genipin forms an interpenetrating scaffold within the hydrogel, allowing for effective drug delivery. Chemotherapeutic drugs can be incorporated into the hydrogel, either singly or in combination, without compromising its thermo-responsiveness. The therapeutic application of this hydrogel in the intratumoral treatment of solid cancers represents a significant advancement in cancer therapy.
Career Highlights
Conn Hastings is affiliated with the Royal College of Surgeons in Ireland, where he continues to push the boundaries of medical research and innovation. His work has garnered attention for its potential to improve treatment outcomes for cancer patients.
Collaborations
Hastings collaborates with notable colleagues, including Helena Kelly and Garry Duffy, who contribute to his research efforts and innovations.
Conclusion
Conn Hastings is a pioneering inventor whose work in developing thermo-responsive hydrogels is poised to make a lasting impact on cancer treatment. His innovative approach and dedication to medical advancements highlight the importance of research in improving patient care.